Horizon Wealth Management LLC Has $240,000 Stock Holdings in Johnson & Johnson $JNJ

Horizon Wealth Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.1% in the second quarter, HoldingsChannel reports. The institutional investor owned 1,571 shares of the company’s stock after selling 139 shares during the period. Horizon Wealth Management LLC’s holdings in Johnson & Johnson were worth $240,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $186.39 on Thursday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $449.07 billion, a price-to-earnings ratio of 17.99, a P/E/G ratio of 2.20 and a beta of 0.40. The firm’s 50 day simple moving average is $182.88 and its 200 day simple moving average is $167.17. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Analyst Ratings Changes

Several research analysts have weighed in on JNJ shares. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. HSBC increased their price target on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.